Drugs / anti-CI135 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06760260 | Jan 2022 → Dec 2025 overdue | acute myeloid leukemia | Hrain Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CI135 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06760260 ↗ |
| Modality | Cell therapy | “anti human CI-135 (FLT3) CAR-T Injection” NCT06760260 ↗ |
| Target | FLT3 | “anti human CI-135 (FLT3) CAR-T Injection” NCT06760260 ↗ |